Merck & Company Inc (MRK)vsOmniAb Inc. (OABI)
MRK
Merck & Company Inc
$120.79
-3.46%
HEALTHCARE · Cap: $285.64B
OABI
OmniAb Inc.
$2.48
-6.77%
HEALTHCARE · Cap: $347.93M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 227164% more annual revenue ($65.77B vs $28.94M). MRK leads profitability with a 13.6% profit margin vs -187.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
OABI
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Intrinsic value data unavailable for OABI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Reasonable price relative to book value
Revenue surging 247.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -20.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : OABI
The strongest argument for OABI centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 247.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
MRK profiles as a value stock while OABI is a hypergrowth play — different risk/reward profiles.
OABI carries more volatility with a beta of 1.15 — expect wider price swings.
OABI is growing revenue faster at 247.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 34/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies via its proprietary OmniAb platform. This advanced technology enables the swift discovery and refinement of highly effective therapies aimed at addressing a wide spectrum of diseases. By leveraging strategic partnerships and collaborations, OmniAb aims to accelerate drug development processes and enhance access to groundbreaking treatments. With a seasoned leadership team and a robust pipeline of candidates, the company is strategically positioned to capitalize on the growing opportunities within the biopharmaceutical industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?